Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)
Close on Nov 17, 2026Market cap $1.78BP/E –Yield –
Agios Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Agios Pharmaceuticals's total assets was $1.11B at Jun 30, 2026. For fiscal 2025 it was $1.30B, down 22.0% from the year before. Over ten years it grew 11.9% a year on average. The highest annual figure on record is $1.66B in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30B | -22.0% |
| FY2024 | Dec 31, 2024 | $1.66B | +77.5% |
| FY2023 | Dec 31, 2023 | $937.12M | -24.3% |
| FY2022 | Dec 31, 2022 | $1.24B | -13.8% |
| FY2021 | Dec 31, 2021 | $1.44B | +68.6% |
| FY2020 | Dec 31, 2020 | $852.95M | -4.2% |
| FY2019 | Dec 31, 2019 | $890.74M | +3.8% |
| FY2018 | Dec 31, 2018 | $858.46M | +39.7% |
| FY2017 | Dec 31, 2017 | $614.40M | -0.8% |
| FY2016 | Dec 31, 2016 | $619.09M | +47.4% |
| FY2015 | Dec 31, 2015 | $420.07M | -14.6% |
| FY2014 | Dec 31, 2014 | $491.90M | +144.5% |
| FY2013 | Dec 31, 2013 | $201.21M | +46.9% |
| FY2012 | Dec 31, 2012 | $137.01M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.11B | -24.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.18B | -23.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.30B | -22.0% |
| Q3 FY2025 | Sep 30, 2025 | $1.39B | -22.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.47B | +90.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.56B | +83.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.66B | +77.5% |
| Q3 FY2024 | Sep 30, 2024 | $1.79B | +77.9% |
| Q2 FY2024 | Jun 30, 2024 | $773.06M | -28.8% |
| Q1 FY2024 | Mar 31, 2024 | $849.71M | -26.2% |
| Q4 FY2023 | Dec 31, 2023 | $937.12M | -24.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.01B | -14.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.09B | -13.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.15B | -13.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.24B | -13.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.18B | -23.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.25B | -33.2% |
| Q1 FY2022 | Mar 31, 2022 | $1.34B | -46.3% |
| Q4 FY2021 | Dec 31, 2021 | $1.44B | +68.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.54B | +69.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.87B | +92.0% |
| Q1 FY2021 | Mar 31, 2021 | $2.49B | +211.2% |
| Q4 FY2020 | Dec 31, 2020 | $852.95M | -4.2% |
| Q3 FY2020 | Sep 30, 2020 | $908.45M | +30.0% |
| Q2 FY2020 | Jun 30, 2020 | $976.14M | +24.5% |
| Q1 FY2020 | Mar 31, 2020 | $799.74M | -2.7% |
| Q4 FY2019 | Dec 31, 2019 | $890.74M | +3.8% |
| Q3 FY2019 | Sep 30, 2019 | $698.62M | -24.8% |
| Q2 FY2019 | Jun 30, 2019 | $783.87M | -21.5% |
| Q1 FY2019 | Mar 31, 2019 | $822.13M | -21.0% |
| Q4 FY2018 | Dec 31, 2018 | $858.46M | +39.7% |
| Q3 FY2018 | Sep 30, 2018 | $929.08M | +35.2% |
| Q2 FY2018 | Jun 30, 2018 | $998.24M | +31.2% |
| Q1 FY2018 | Mar 31, 2018 | $1.04B | +86.6% |
| Q4 FY2017 | Dec 31, 2017 | $614.40M | -0.8% |
| Q3 FY2017 | Sep 30, 2017 | $687.20M | +2.3% |
| Q2 FY2017 | Jun 30, 2017 | $760.60M | – |
| Q1 FY2017 | Mar 31, 2017 | $557.32M | – |
| Q4 FY2016 | Dec 31, 2016 | $619.09M | – |
| Q3 FY2016 | Sep 30, 2016 | $672.04M | – |
See a number that looks wrong?